文献速递消化道肿瘤与早癌肝病

非酒精性脂肪性肝病时代奥沙利铂肝损伤的临床谱与诊断

The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-09-30

奥沙利铂是III期结直肠癌辅助化疗的主要药物,肝损伤表现从临床试验中42%至57%患者的轻度肝酶升高到罕见的严重损伤导致急性肝衰竭。慢性亚临床损伤发生率高达78%,可表现为结节性再生性增生、门管区硬化及非肝硬化性门脉高压,诊断可能被非酒精性脂肪性肝病混淆,慢性损伤的长期结局尚不明确。

要点

  • 奥沙利铂肝损伤谱从轻度肝酶升高(临床试验中42%至57%)到罕见严重损伤导致急性肝衰竭。
  • 慢性亚临床损伤发生率高达78%,可表现为结节性再生性增生、门管区硬化及非肝硬化性门脉高压。
  • 诊断可能被非酒精性脂肪性肝病混淆,慢性损伤的长期结局尚不明确。

核心结论

  • 奥沙利铂肝损伤的临床谱包括轻度肝酶升高、罕见严重损伤导致急性肝衰竭以及慢性亚临床损伤,后者可表现为结节性再生性增生、门管区硬化和非肝硬化性门脉高压。
  • 诊断可能被非酒精性脂肪性肝病混淆,慢性损伤的长期结局尚不明确。

主要发现

  • 临床试验中42%至57%的患者出现轻度肝酶升高。
  • 慢性亚临床损伤发生率高达78%。
  • 慢性损伤源于内皮细胞损伤和结构扭曲,可在数年后表现为结节性再生性增生、门管区硬化和非肝硬化性门脉高压。
  • 罕见的严重肝损伤可导致急性肝衰竭。

局限性

  • 慢性损伤的长期结局尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oxaliplatin is an alkylating agent given with fluorouracil and leucovorin as a mainstay adjuvant chemotherapy for stage III colorectal cancer (CRC). Liver injury from oxaliplatin ranges from mild liver enzyme increases in 42% to 57% of patients in clinical trials1 to rare severe injury leading to acute liver failure.2 Chronic injury from endothelial cell damage and architectural distortion may manifest years later with nodular regenerative hyperplasia (NRH), portal sclerosis, and noncirrhotic portal hypertension (NCPH).2,3 Chronic subclinical injury occurs in up to 78% of patients.3 Diagnosis may be confounded by nonalcoholic fatty liver disease (NAFLD), and long-term outcomes from chronic injury are unclear.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kim HP, Navarro V, Zacks S, et al. The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2020. PMID: 33007507. doi:10.1016/j.cgh.2020.09.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。